Table 2 Pre-clinical use of hAEC in lung disease
No | Pathologic condition | Type of HCT/Ps | Mechanism of action | Administered dose | Route of administration | References |
|---|---|---|---|---|---|---|
1 | Lipopolysaccharide-induced lung injury | hAECs | Reducing lung inflammatory mediators | 1.8 × 108 (intratracheal) | Intratracheal | [86] |
0.9 × 108 (intravenous) | Intravenous | |||||
2 | Lung fibrosis | hAECs | Surfactant production | 1 × 106 | Intravenous | [88] |
Differentiation to pneumocytes | ||||||
Immunomodulation | ||||||
3 | Bleomycin-induced lung injury | hAECs | Reducing lung inflammatory mediators | 4 × 106 | Intraperitoneal | [27] |
Reducing leukocyte infiltration | ||||||
Preventing collagen deposition | ||||||
4 | Bleomycin-induced lung injury | hAECs | Reducing macrophage infiltration | 4 × 106 | Intraperitoneal | [94] |
Switching M1 to M2 macrophages | ||||||
5 | Idiopathic pulmonary Fibrosis | hAEC-derived exosomes | Promoting proliferation of bronchioalveolar stem cell Increasing macrophage phagocytosis Reducing neutrophil myeloperoxidase Suppressing T cell proliferation | 10 μg | Intranasal | [103] |
6 | Ventilation-induced lung injury | hAECs | Differentiated into type I and II alveolar cells | 120 × 106 (total | Intratracheal | [190] |
Reducing fibrosis | l dose) | Intravenous | ||||
7 | Bleomycin-induced lung injury | hAECs | Reducing lung inflammation | 4 × 106 | Intraperitoneal | [198] |
Reducing fibroblast activation | ||||||
8 | Ventilation-induced lung injury | hAECs | Reducing T cell infiltration | 0.9 × 108 (both routes) | Intratracheal | [199] |
Intravenous | ||||||
9 | Bronchopulmonary dysplasia | hAECs | Reducing lung inflammatory mediators | 0.1 × 106 | Intratracheal | [200] |
Reducing leukocyte infiltration | Intravenous | |||||
10 | Ventilation-induced lung injury | hAECs | Regenerating lung tissue | 0.3 × 108 | Intravenous | [201] |